Pharmaceuticals

Collaborating for a cure to GvHD

Our Work

Partner

Videos

Work With Us

Collaborate With Patients and Medical Staff

GVHD presents unique challenges and opportunities for therapeutic innovation. This platform provides in-depth insights into the latest advancements in GVHD research, drug development, and clinical trials. We aim to foster collaboration and knowledge-sharing among industry leaders to accelerate the development of effective treatments. By leveraging cutting-edge research and clinical data, we strive to enhance the efficacy and safety of GVHD therapies, ultimately improving patient outcomes and quality of life.

Partner With Us

Every year approximately 50,000 patients undergo a bone marrow or stem cell transplant. Approximately 50% survive. Of those survivors, approximately 50% are diagnosed with Graft vs. Host Disease (GVHD). There are currently 100,000 survivors in the U.S.

There is not yet a cure for GvHD. Treatment for the disease involves a series of immunosuppressant drugs, which in and of themselves have significant side effects and can-do long-term damage to the patient’s body. For example, a very common side effect is cataracts, regardless of a patient’s age. By raising funding and awareness around GVHD research, we’re championing new treatments to help improve the lives of the thousands of people living with this debilitating disease.

The Meredith A. Cowden Foundation is also a founding member of the GVHD Alliance, a collaboration of six organizations with the aim of (1) supporting those affected by GvHD and (2) understanding and addressing unmet needs, as well as (3) providing helpful resources to create change.

Our Impact

The reach and impact of the Foundation

Your Title Goes Here

Your Title Goes Here

Your Title Goes Here

Partner With Us

How to partner with the Meredith A. Cowden Foundation

Option 1

Donec nec justo eget felis facilisis fermentum. Aliquam porttitor mauris sit amet orci. Aenean dignissim pellentesque felis.

Option 2

Donec nec justo eget felis facilisis fermentum. Aliquam porttitor mauris sit amet orci. Aenean dignissim pellentesque felis.

Option 3

Donec nec justo eget felis facilisis fermentum. Aliquam porttitor mauris sit amet orci. Aenean dignissim pellentesque felis.

Video Repository

Pharma Interest Focus